CEO Markus Renschler (Cyteir Therapeutics)
With crossover round in its pocket, synthetic lethality-focused Cyteir Therapeutics eyes a jump onto Nasdaq
Cyteir Therapeutics CEO Markus Renschler has his eye on the market. The Celgene vet pulled in an $80 million crossover round on Thursday to fuel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
